Drug Profile
Research programme: oxytocin intranasal - Pastorus Pharma
Latest Information Update: 04 Dec 2021
Price :
$50
*
At a glance
- Originator Shin Nippon Biomedical Laboratories
- Developer Pastorus Pharma; Shin Nippon Biomedical Laboratories
- Class Amides; Amines; Analgesics; Antihaemorrhagics; Antihyperglycaemics; Antimigraines; Behavioural disorder therapies; Hormones; Macrocyclic lactams; Obesity therapies; Oxytocics; Pyrrolidines
- Mechanism of Action Neurotransmitter modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autistic disorder
Most Recent Events
- 15 Oct 2013 No development reported for Autistic disorder in USA (Intranasal)
- 10 Feb 2011 Early research in Autistic disorder in USA (Intranasal)